Antimicrobial Susceptibility Testing Market Analysis | 2022-2028

“The Antimicrobial Susceptibility Testing Market was estimated at US$ 3.4 billion in 2021 and is expected to grow at a CAGR of 5.86% during 2022-2028 to reach US$ 6.28 billion in 2028”.

Wish to get a free sample? Register Here

Market Dynamics

Introduction

Antimicrobial Susceptibility Testing (AST) is a laboratory procedure used to determine the effectiveness of antibiotics against specific bacteria. It helps identify which antimicrobial agents can inhibit or kill the bacteria, guiding clinicians in selecting appropriate treatments for infections and ensuring effective management of antimicrobial resistance.

Antimicrobial susceptibility testing (AST) validates susceptibility, detects resistance, and informs patient therapy selection. The testing can help doctors choose the right drugs and dosage for difficult-to-treat infections. Antibiotic resistance is a critical global health hazard that requires worldwide action. It has become a huge global health hazard as a result of antibiotic overuse.

Current antimicrobial susceptibility testing (AST) procedures, which are used to probe for resistant or nonresistant (susceptible) phenotypes of infections, often take two to one week from the time of sample collection.

Furthermore, antimicrobial susceptibility testing (AST) aims to ensure that appropriate antibiotics are prescribed to infected individuals and also aids in the identification of resistance isolates with defined resistance mechanisms to infection prevention and control, thereby driving the antimicrobial susceptibility testing market growth.

Market Drivers

Over the forecast period, the increased frequency of infectious diseases is expected to fuel the global antimicrobial susceptibility testing market growth. According to the World Health Organization (WHO) Fact Sheet published in October 2021, 1.5 million individuals died from tuberculosis (TB) in 2020 (including 214,000 HIV patients). According to the same source, tuberculosis is the world's 13th leading cause of death and, after COVID-19, the second leading infectious killer.

Furthermore, the antimicrobial susceptibility testing market is predicted to rise significantly as a result of increased product releases by key players. In 2019, for example, F. Hoffman-La Roche Ltd., a research-based healthcare company, announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect antibiotic resistance in tuberculosis DNA.

Increased government awareness activities for antimicrobial resistance and its control are projected to drive growth in the worldwide antimicrobial susceptibility testing market. For example, the Global Sepsis Alliance, based in the United States, is a non-profit charity organization whose aim is to provide global leadership in order to minimize the global burden of sepsis. It was formed in 2010 to increase global awareness of sepsis. The Global Sepsis Alliance now includes over 100 organizations from throughout the world. Sepsis is a potentially fatal illness that arises when the body's response to an infection causes tissue damage.

Automated antimicrobial susceptibility testing systems are expensive and contain advanced functionality. The advantages of automated antimicrobial susceptibility testing systems include reduced detection time, testing accuracy, and others; however, the high cost of such systems may act as a hindrance to the worldwide antimicrobial susceptibility testing market growth.

According to an article published in July 2020 by the National Center for Biotechnology Information, a collection of databases relevant to biotechnology and biomedicine, the high cost of molecular testing for antimicrobial susceptibility acts as an effective barrier to the implementation of new technologies.

According to the same source, testing costs also include clinical samples and cultivation in microbiology labs, which are operations performed prior to antibiotic susceptibility testing (AST). When the costs of the MALDI-TOF apparatus, reagents, pharmacist time, and the antimicrobial stewardship program are added together, the overall cost for mass spectrometry-based AST is around € 79 (US$ 83.3) per patient.

Governments all across the world are focusing intensively on antimicrobial resistance policies and tactics. Furthermore, activities to raise awareness of antimicrobial resistance and reduce antimicrobial abuse are assisting in educating decision-makers, regulatory agencies, and other end users about antimicrobial resistance prevention. Among the noteworthy government programs aimed at combating multidrug resistance are:

• The UK government released a 20-year strategy and a 5-year action plan to combat AMR in 2019. Previously, in 2018, the United Kingdom issued a five-year national action plan outlining the United Kingdom's role in combating the growing worldwide problem of antimicrobial resistance. The plan's goal was to reduce drug-resistant diseases by 10% by 2025 and human antibiotic use by 15%. The plan also aims to eliminate healthcare-related infections by 2024, paving the way for funding in small biotech firms trying to reduce resistant illnesses.
• The National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), 2020-2025, was announced in October 2020 to improve the health and well-being of all Americans by altering the trajectory of antibiotic resistance. This strategy prioritizes infection prevention and control to reduce the spread of resistant illnesses and maximize antibiotic use.

Several investments/guidelines in the market have been directed in recent years, which would boost the overall market. Some of them are:

• As a growing number of pathogenic bacteria develop antibiotic resistance and novel forms of resistance emerge, doctors must prioritize antimicrobial susceptibility testing (AST). A rapid multiplexed AST platform provides minimum inhibitory concentrations (MICs) in hours at a reasonable cost, allowing for the rapid determination of effective targeted therapy, resulting in shorter hospital stays, fewer laboratory tests, and lower morbidity and mortality, as well as associated healthcare costs.

Recent Developments

The market for antimicrobial susceptibility testing is highly competitive. The market players are highly focused on mergers, expansions, and product approvals, to sustain in this market. Increasing test launches are projected to boost market growth throughout the forecast period. There are a few key developments mentioned below:

• In 2019, F. Hoffmann-La Roche Ltd., a research-based healthcare company, announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect antibiotic resistance within tuberculosis DNA.
• In 2018, Danaher subsidiary Beckman Coulter Inc. announced the introduction of its DxM MicroScan WalkAway system, a diagnostic solution for bacterial identification and antibiotic susceptibility testing for microbiology laboratories.

Segments Analysis

By Product Type

The market is further segmented into manual antimicrobial susceptibility testing products, automated laboratory instruments, and consumables. The market based on manual antimicrobial susceptibility testing products is further segmented into susceptibility testing disks, mic strips, and susceptibility plates.

By Application Type

The market is segmented into antibacterial, antifungal, anti-parasitic, and antiviral.

By Technology Type

The antimicrobial susceptibility testing market has been divided into disk diffusion, rapid automated ast, broth dilution, gradient diffusion, and genotypic methods.

By End-User Type

The market is classified into hospitals, pathology/diagnostic laboratories, research and academic institutes, pharmaceutical and biotechnology companies, contract research organizations, and others.

Regional Analysis

The antimicrobial susceptibility testing market is broken down geographically into geographies, namely North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

Key Players

The following are the key players in the Antimicrobial Susceptibility Testing Market (arranged alphabetically)

• Accelerate Diagnostics, Inc.
• Alifax S.r.l. Italy
• BIOMÉRIEUX
• Becton, Dickinson, and Company
• Bio-Rad Laboratories, Inc.
• Bruker
• CONDALAB
• Creative Diagnostics
• Danaher
• ELITechGroup
• Flinn Scientific
• HiMedia Laboratories
• Hoffmann-La Roche Ltd.
• Mast Group Ltd.
• Merck KGaA
• Nissui Pharmaceutical Co., Ltd.
• Resistell AG
• Synbiosis
• Thermo Fisher Scientific Inc.
• Zhuhai DL Biotech Co., Ltd.

The overall competitive landscape has been affected due to these mergers and acquisitions. 

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Write to us at sales@stratviewresearch.com

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research:

Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.